Skip Navigation Links
Skip Navigation LinksBaylor Health CareResearchBaylor Scott & White Research InstituteDallasResearch Institutes and CentersBaylor Institute for Immunology ResearchFundingPharmacometric Optimization of Second-Line Drugs for MDR Tuberculosis Treatment

Pharmacometric Optimization of Second-Line Drugs for MDR Tuberculosis Treatment



Grant number: 1R01AI116155-01 

Principal Investigator: Helen McIlleron, PhD (University of Cape Town) &Tawanda Gumbo, MD 

Funding Organization: National Institute of Allergy & Infectious Diseases 

Project Start: February 15, 2015

Project End: January 31, 2020



Dr. Gumbo will perform compartmental pharmacokinetic analysis for the hollow fiber studies and identify the mathematical models for the relationship between acquired drug resistance, microbial effect, and drug concentration. He will also perform Monte Carlo simulations. Tasks will include work to establish semi-mechanistic mathematical models, pharmacokinetic/pharmacodynamics modeling, statistical analyses of laboratory results, examination of thresholds associated with optimal efficacy using machine learning methods, as well as help with translation from pre-clinical models to patients.

Copyright © 2019 Baylor Scott & White Health All Rights Reserved.   |   3500 Gaston Avenue, Dallas, TX 75246-2017   |   1.800.9BAYLOR
Site Map   |   Privacy Terms & Patient Rights   |   Terms of Use